AEMPS Boosts Visibility of Drug Import and Export Data with New Updates
- The Spanish Agency for Medicines and Health Products (AEMPS) is increasing the transparency of pharmaceutical import and export data through new reporting requirements and visibility tools, according to...
- AEMPS is launching a new phase of transparency specifically targeting the foreign trade of medicinal products.
- The agency is detailing specific changes to the existing regulatory framework to ensure that trade flows are more accurately tracked and reported.
The Spanish Agency for Medicines and Health Products (AEMPS) is increasing the transparency of pharmaceutical import and export data through new reporting requirements and visibility tools, according to a June 22, 2026, agency announcement. The initiative introduces changes to foreign trade protocols to provide more granular data on the movement of medicines across Spanish borders.
What changes is AEMPS implementing for pharmaceutical trade?
AEMPS is launching a new phase of transparency specifically targeting the foreign trade of medicinal products. According to the agency, the updates focus on providing greater visibility into the data generated by the import and export of pharmaceuticals.
The agency is detailing specific changes to the existing regulatory framework to ensure that trade flows are more accurately tracked and reported. These modifications affect how data is collected and presented regarding medicines entering and leaving the Spanish market.
How will these transparency measures affect foreign trade?
The new protocols require more detailed reporting on the volume and nature of pharmaceutical shipments. This shift moves the agency toward a more transparent system for monitoring the international movement of healthcare products.
Pharmaceutical companies engaged in the import and export of medicines in Spain must adhere to these updated visibility standards. The agency’s goal is to create a clearer record of trade activities to better monitor the availability and distribution of medicines.
Why is the agency prioritizing trade data visibility?
AEMPS is implementing these changes to improve the oversight of the pharmaceutical supply chain. By increasing the visibility of import and export data, the regulator can more effectively track the flow of medicines and identify potential disruptions in the supply of essential drugs.
This move aligns with broader regulatory efforts to prevent medicine shortages by maintaining accurate, real-time data on the movement of products between Spain and its international trading partners.